➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
Merck
Express Scripts
Harvard Business School

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

FERRIPROX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Ferriprox, and when can generic versions of Ferriprox launch?

Ferriprox is a drug marketed by Chiesi and is included in three NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty-five countries.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deferiprone profile page.

US ANDA Litigation and Generic Entry Outlook for Ferriprox

Ferriprox was eligible for patent challenges on October 14, 2015.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for FERRIPROX
Drug Prices for FERRIPROX

See drug prices for FERRIPROX

Recent Clinical Trials for FERRIPROX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hadassah Medical OrganizationPhase 2/Phase 3
SocraMetrics GmbHPhase 1
SocraTec R&D GmbHPhase 1

See all FERRIPROX clinical trials

Pharmacology for FERRIPROX
Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Paragraph IV (Patent) Challenges for FERRIPROX
Tradename Dosage Ingredient NDA Submissiondate
FERRIPROX TABLET;ORAL deferiprone 021825 2016-01-29

US Patents and Regulatory Information for FERRIPROX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 RX Yes Yes   Start Trial   Start Trial   Start Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Medtronic
Colorcon
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.